Resident Curriculum: Caring for Patients with Intellectual Disabilities
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- This finding is particularly relevant for individuals with pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: new Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who where treated with semaglutide (Ozempic) compared to those receiving a placebo.The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated meaningful weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. However,it’s crucial to note that the trial did *not* meet its primary endpoint of reducing MACE,despite the significant weight loss observed in the semaglutide group (an average of approximately 15% of body weight).
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 3.7 | 2.9 |
| Non-Fatal Stroke | 2.6 | 2.2 |
| Non-Fatal Heart Attack | 1.2 | 0.8 |
| MACE (Combined) | 6.5 | 4.9 |
Who is Affected? Understanding the patient Population
This finding is particularly relevant for individuals with pre-existing cardiovascular disease. The SELECT trial specifically enrolled participants with a history of established cardiovascular disease, including heart attack, stroke, or peripheral artery disease. It’s significant to emphasize that the results do *not* necessarily apply to individuals with obesity who do not have existing heart conditions. Though,the findings raise questions about the potential for increased risk even in those without a prior history,especially given the widespread use of semaglutide for weight loss.
Why Dose This Matter? The Implications for Clinical Practice
The SELECT trial challenges the prevailing narrative surrounding semaglutide and other GLP-1 receptor agonists. Previously, these medications were often viewed as having a neutral or even beneficial effect on cardiovascular health. This new data suggests a more nuanced picture, highlighting the importance of careful patient selection and risk-benefit assessment. Clinicians will need to weigh the potential benefits of weight loss against the potential for increased cardiovascular risk, particularly in vulnerable populations.
Timeline of Events & Key Developments
- August 17,2023: Results of the SELECT